Holen Sie sich die Stockscreener-App
0.00
100.00%
-17.42
Handel nachbörslich:
17.25
17.25
+
Schlusskurs vom Vortag:
$17.42
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$424.03M
Einnahmen:
$4.66M
Nettoeinkommen (Verlust:
$-110.22M
KGV:
0.00
EPS:
-4.5634
Netto-Cashflow:
$-84.82M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$19.92
Puretech Health Plc Adr Stock (PRTC) Company Profile
Firmenname
Puretech Health Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare PRTC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
0.00 | 424.03M | 4.66M | -110.22M | -84.82M | -4.5634 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
Puretech Health Plc Adr Aktie (PRTC) Neueste Nachrichten
PureTech Health issues shares to executives under RSU plan - Investing.com
PRTCY | PURETECH HEALTH PLC ADR Institutional Ownership - Quiver Quantitative
PRTCY | PURETECH HEALTH PLC ADR Stock Data, Price & News - Quiver Quantitative
PureTech Health issues shares to non-executive directors - Investing.com
PureTech Health issues shares to executives under vesting plan - Investing.com
PureTech Health's Celea Therapeutics Launches Phase 3 SURPASS-IPF Trial for Deupirfenidone in Idiopathic Pulmonary Fibrosis - Kalkine Media
PureTech Health Directors Invest Heavily with GBP 1.19 Share Acquisitions - Kalkine Media
Why PureTech Health (LSE:PRTC) Directors Are Increasing Their Shareholdings - Kalkine Media
PureTech spins out Celea with $180m financing for IPF drug - Investing.com
0VQ0 Forecast — Price Target — Prediction for 2027 - TradingView
PureTech Health ADR (PRTC) Edges Higher Amidst Modest UptickBackspread Trade - dars.gov.et
PureTech Health (PRTCY) Dividend Yield (TTM) - Zacks Investment Research
PureTech Health (PRTCY) Market Cap - Zacks Investment Research
PRTCY: PureTech HealthComparison to Industry - Zacks Investment Research
PureTech Health (PRTCY) - Zacks Investment Research
PRTC News | PURETECH HEALTH PLCADR (NASDAQ:PRTC) - ChartMill
PRTC Stock Price, Quote & Chart | PURETECH HEALTH PLCADR (NASDAQ:PRTC) - ChartMill
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference - ChartMill
PureTech Health Plc (LSE:PRTC) Share Price, History, & News - The Twelfth Magpie
PureTech Health Seaport listing lifts FTSE 350 sentiment surge? - Kalkine Media
PureTech Health H2 Earnings Call Highlights - Yahoo Finance
PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS - MarketBeat
PureTech Announces Intention to Voluntarily Delist American Depos - The National Law Review
[20-F] PureTech Health plc Files Annual Report (Foreign Issuer) | PRTC SEC FilingForm 20-F - Stock Titan
Earnings call transcript: PureTech Health’s mixed FY2025 results spark stock drop - Investing.com
PureTech Health (PRTC) ends Nasdaq ADS listing, focuses trading on LSE - Stock Titan
PureTech to Exit Nasdaq Listing and Consolidise Trading in London - Yahoo Finance UK
PureTech Health to delist ADSs from Nasdaq, focus on LSE - Investing.com
PureTech Health to delist ADSs from Nasdaq, focus on LSE By Investing.com - Investing.com South Africa
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange - marketscreener.com
PureTech Announces Annual Results for Year Ended December 31, 2025 - ChartMill
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - ChartMill
PureTech Health (PRTC) Expected to Announce Earnings on Wednesday - MarketBeat
0VQ.DE Stock Price, Quote & Chart | PURETECH HEALTH PLC (FRA:0VQ) - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in March - MarketBeat
PureTech Health: Notice of Results - ChartMill
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers - ChartMill
PureTech publishes Phase 2b trial results for IPF drug candidate - Investing.com
Is PureTech Health in FTSE AIM 100? - Kalkine Media
Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 140.8% - MarketBeat
Short Interest in Citizens Bancorp of Virginia, Inc. (OTCMKTS:CZBT) Grows By 141.4% - Defense World
Pacer American Energy Independence ETF (NYSEARCA:USAI) Sees Large Increase in Short Interest - Defense World
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - ChartMill
Lansdowne Partners UK LLP Takes Position in PureTech Health PLC Sponsored ADR $PRTC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 36.2% in February - MarketBeat
PureTech Health in the FTSE landscape as technical momentum shifts - Kalkine Media
PureTech to Present at the Leerink Partners Global Healthcare Conference - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update - MarketBeat
PureTech CEO to present at J.P. Morgan Healthcare Conference - Investing.com
PureTech Health appoints Robert Lyne as permanent CEO By Investing.com - Investing.com UK
Finanzdaten der Puretech Health Plc Adr-Aktie (PRTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):